 Ultomiris, the successor to Alexion Pharmaceuticals Incs NASDAQ: ALXN paroxysmal nocturnal hemoglobinuria PNH drug Soliris, is on track for another blockbuster year. The drug posted 701 million in sales during 1H of 2021, Alexion said in a recent securities filing, a whopping 48 increase over the same period in 2020. 